Dosing Afrezza: It’s Not that Complicated

View at publisher
Authors: Steve V. Edelman, Thomas C. Blevins, Christopher G. Parkin, Irl B. Hirsch
Cited by: 1
References: 13

Abstract

Afrezza inhaled insulin offers a unique alternative to subcutaneous insulin delivery, providing a rapid onset to effectively manage postprandial glucose spikes with a short duration of action that minimizes delayed postprandial hypoglycemia. Although Afrezza has been commercially available for more than a decade, its adoption has been limited by lack of clinician awareness, confusion about dosing, and skepticism about its efficacy and safety. This article presents our perspectives on Afrezza regarding dosing and titration strategies, patient selection and education, and other practical considerations.

Fields of Study & Subjects

Diabetes Management and Research Hyperglycemia and glycemic control in critically ill and hospitalized patients Advanced Drug Delivery Systems

Publication details

Journal / source
Diabetes Technology & Therapeutics
Publisher
SAGE Publications
Volume
28
Issue
1_suppl
Pages
8S–13S
Publication date
1 February 2026
Language
EN